34653 Atopic dermatitis treatment patterns and patient burden in Russia and Poland

Abstract

Background: Information on atopic dermatitis (AD) treatment patterns and disease burden is limited in Russia and Poland. We aimed to understand the treatment paradigm and impact of AD on patients in these countries. Methods: Data were drawn from the 2021 AD Disease Specific Programme, a cross-sectional survey of Russian and Polish dermatologists and patients. Physicians completed patient record forms capturing clinical and demographic characteristics including treatment patterns. Patients filled out a questionnaire that included DLQI, POEM, WPAI, and EQ5D-5L. Comparisons between disease severity were made using a pairwise T-test. Results: 340 adult AD patients (152 Russia, 188 Poland) were included of whom 284 (136 Russian, 148 Poland) provided PROs. Mean overall age 30.5 years, 43% male. Physician-reported subjective severity was 101 mild, 204 moderate, 35 severe. Of 332 patients receiving prescribed treatment, 78% received emollients, 77% topical corticosteroids, 43% topical calcineurin inhibitors, 14% systemic corticosteroids, 8% systemic immunosuppres-sants. Only 3% received a biologic, all in Russia. Mean number of current treatments per patient was 3.2. Physicians reported only 35% of patients were currently improving, 26% were stable, but 39% either changeable or deteriorating. Mean patient-reported burden for mild and moderate/severe patients was, respectively: DLQI 6.6 vs 12.0, POEM 7.3 vs 14.1, EQ-5D 0.95 vs 0.87 and overall work impairment 18.8 vs 39.3% (all P < .001). Conclusions: In Russia and Poland, mainstays of treatment appear to be emollients/corticosteroids despite almost 40% of patients being changeable or deteriorating. Patient burden was also substantial, particularly in moderate/severe patients, indicating a high unmet medical need.